Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Treasury Shares (2020 - 2026)

Immunovant filings provide 6 years of Treasury Shares readings, the most recent being $3.9 million for Q4 2025.

  • Quarterly Treasury Shares rose 9.81% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, up 9.81% year-over-year, with the annual reading at $3.2 million for FY2025, 6.52% down from the prior year.
  • Treasury Shares hit $3.9 million in Q4 2025 for Immunovant, down from $4.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.0 million in Q2 2023 and bottomed at $931923.0 in Q2 2021.
  • Average Treasury Shares over 5 years is $3.5 million, with a median of $3.7 million recorded in 2023.
  • The largest annual shift saw Treasury Shares skyrocketed 2568.32% in 2021 before it dropped 20.02% in 2024.
  • Immunovant's Treasury Shares stood at $3.5 million in 2021, then increased by 28.05% to $4.5 million in 2022, then decreased by 16.47% to $3.8 million in 2023, then decreased by 6.48% to $3.5 million in 2024, then rose by 9.81% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Treasury Shares are $3.9 million (Q4 2025), $4.3 million (Q3 2025), and $4.7 million (Q2 2025).